Coronary stents have revolutionized myocardial revascularization and are constantly evolving – a fact that have improved the clinical outcomes of patients with ischemic heart disease. The bioresorbable stent (BVS) is part of this evolution with its very attractive concept. Among other benefits, its complete resorption over time could reduce the risk of restenosis and late thrombosis. These stents are controversial and their use is currently suspended. By this work we aim to contribute to the debate.

Main Purpose short and mid-term results of BVS implantation at Blida University Hospital. Secondary Purpose epidemiological profile of our patients treated with BVS.

We conducted a retrospective, descriptive, single-center study of 51patients treated with BVS, between January 1, 2015 and May 31, 2016.

The mean age of our patients was 54 years old and 78% were male. 48% had diabetes, 42% were hypertensive and 38% were smokers. There was at least one history of documented cardiovascular disease in 47% of cases. 98% of patients were treated for stable coronary artery disease when only one, was treated for ST elevation myocardial infarction (STEMI). The majority of our patients had mono-troncular coronary lesion (84%). The most affected segments were the mid-left anterior descending artery (LAD) (59%), proximal LAD (20%) and mid-right coronary artery (12%). We had 100% of primary procedural success. The greater part of implanted stents were of large diameter (80% above 3mm) and short length (76% less than 20mm). We observed only one adverse event in follow-up, this was an acute stent thrombosis occurring in the week following the angioplasty of the only patient whose initial indication was a STEMI.

Our experience was generally satisfactory in this relatively young population with rather simple coronary lesions. A single acute stent thrombosis was observed in a patient with a complex lesion in a STEMI context.